title: [Preparation and in vitro killing effect of adriamycin-loaded immunonanosphere against hepatoma led by F (ab')2 Fragment of monoclonal antibodies].
abstract: OBJECTIVE
  To study the preparation method and in vitro killing effect of adriamycin (ADR)-loaded human serum albumin (HSA) immunonanosphere (HAb18 F(ab')2-ADR-HSA-NP) against hepatoma led by F(ab')2 fragment of human hepatoma specific monoclonal antibody HAb18.
  
  
  METHODS
  After ADR loaded HSA nanosphere (ADR-HSA-NP) was prepared in the emulsifying high temperature solidifying way, HAb18 F(ab')2-ADR-HSA-NP was prepared using the modified N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) method. In vitro binding characters of HAb18 F(ab')2-ADR-HSA-NP and ADR-HSA-NP and hepatoma cell SMMC-7721 were observed under optical microscopy and electronic microscopy. In vitro effects of killing hepatoma cell SMMC-7721 of two microspheres were determined using the method of 3H-TdR.
  
  
  RESULTS
  The surfaces of HAb18 F(ab')2-ADR-HSA-NP gave out bright yellow-green fluorescence after it was dyed with fluorescent agent, whereas ADR-HSA-NP did not give out fluorescence. HAb18 F(ab')2-ADR-HSA-NP could integrate with hepatoma cell SMMC-7721 and effectively killed hepatoma cell SMMC-7721 with dose dependence, but ADR-HSA-NP could not obviously integrate and kill SMMC-7721. Neither of the two microspheres could bind and kill human large intestine cancer cell SW1116.
  
  
  CONCLUSIONS
  HAb18 F(ab')2-ADR-HSA-NP has a good character for in vitro specific targeting to bind and kill human hepatoma cell.
authors.affiliation: Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Yunchun
authors.initials: Y
authors.lastname: Li
authors.forename: Meiying
authors.initials: M
authors.lastname: Cai
authors.forename: Zhongqiong
authors.initials: Z
authors.lastname: Wang
authors.forename: Xiaobo
authors.initials: X
authors.lastname: Liu
authors.forename: Zhenglu
authors.initials: Z
authors.lastname: Liang
mesh_terms: D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000276:immunology; D000912:Antibodies, Neoplasm / Q000096:biosynthesis / Q000276:immunology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000473:pathology*; D004317:Doxorubicin / Q000008:administration & dosage* / Q000494:pharmacology; D016503:Drug Delivery Systems; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology*; D008113:Liver Neoplasms / Q000276:immunology / Q000473:pathology*; D008863:Microspheres; D036103:Nanotechnology; D012709:Serum Albumin; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D007140:Immunoglobulin Fab Fragments; D012709:Serum Albumin; D004317:Doxorubicin